Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Ingalls & Snyder LLC

Ingalls & Snyder LLC trimmed its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 34.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,724 shares of the medical research company’s stock after selling 3,463 shares during the quarter. Ingalls & Snyder LLC’s holdings in Edwards Lifesciences were worth $498,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Harbor Capital Advisors Inc. raised its stake in shares of Edwards Lifesciences by 2.5% during the 4th quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company’s stock worth $824,000 after buying an additional 273 shares during the period. Nordea Investment Management AB raised its stake in shares of Edwards Lifesciences by 34.6% during the 4th quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock worth $301,355,000 after buying an additional 1,043,484 shares during the period. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST raised its stake in Edwards Lifesciences by 6.7% in the 4th quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company’s stock valued at $355,344,000 after purchasing an additional 300,000 shares during the last quarter. Sivik Global Healthcare LLC acquired a new position in Edwards Lifesciences in the 4th quarter valued at $3,702,000. Finally, Avanza Fonder AB acquired a new position in Edwards Lifesciences in the 4th quarter valued at $4,845,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Performance

NYSE EW opened at $75.96 on Friday. The stock has a market cap of $44.80 billion, a PE ratio of 10.96, a P/E/G ratio of 3.64 and a beta of 1.10. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The stock has a fifty day simple moving average of $72.51 and a 200-day simple moving average of $69.36.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Equities analysts anticipate that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.

Analyst Ratings Changes

EW has been the subject of several recent research reports. Piper Sandler increased their price objective on Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research note on Wednesday. Royal Bank of Canada reissued an “outperform” rating and issued a $85.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday. Evercore ISI reduced their price objective on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a research note on Wednesday. Truist Financial reissued a “hold” rating and issued a $78.00 price objective (up from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Finally, Sanford C. Bernstein raised Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Edwards Lifesciences has an average rating of “Hold” and an average target price of $79.95.

Insider Buying and Selling

In related news, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the transaction, the chief financial officer now owns 30,561 shares of the company’s stock, valued at approximately $2,315,301.36. This represents a 26.91 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 2,500 shares of the stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $74.08, for a total value of $185,200.00. Following the transaction, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,717,841.12. The trade was a 9.73 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 20,750 shares of company stock valued at $1,564,255. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.